Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience

doi:10.12998/wjcc.v11.i3.566

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2407)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1383

Figures (1-1)

290

Tables (1-4)

236

Sum=2017

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

105

Download

285

Sum=390

Jan 26, 2023 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jan 26, 2023; 11(3): 566-575
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.566

Full Size Figure Download Figure

Figure 1 Clinical outcomes. A: Kaplan-Meier curve for complete or partial remission; B: 24 h urinary protein quantification trend after Rituximab (RTX) in 9 patients with refractory idiopathic membranous nephropathy (IMN); C: Albumin trend after RTX in 9 patients with refractory IMN; D: Serum creatinine trend after RTX in 9 patients with refractory IMN. UTP: Urinary protein quantification; ALB: Albumin; SCr: Serum creatinine.

Citation: Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2023; 11(3): 566-575
URL: https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i3.566